Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.

Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F.

Blood. 2010 May 20;115(20):4061-70. doi: 10.1182/blood-2008-06-163386. Epub 2010 Mar 11.


A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.

Lamant L, Dastugue N, Pulford K, Delsol G, Mariamé B.

Blood. 1999 May 1;93(9):3088-95.


Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.

Bohling SD, Jenson SD, Crockett DK, Schumacher JA, Elenitoba-Johnson KS, Lim MS.

Leuk Res. 2008 Mar;32(3):383-93. Epub 2007 Aug 27.


Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.

Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M, Al Saati T, Felsher DW, Delsol G, Meggetto F.

Cancer Biol Ther. 2007 Aug;6(8):1318-23. Epub 2007 May 29.


Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.

Turner SD, Tooze R, Maclennan K, Alexander DR.

Oncogene. 2003 Oct 30;22(49):7750-61.


Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).

Ouyang T, Bai RY, Bassermann F, von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J.

J Biol Chem. 2003 Aug 8;278(32):30028-36. Epub 2003 May 14.


Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.

Oncogene. 2007 Aug 16;26(38):5606-14. Epub 2007 Mar 12.


TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.

Armstrong F, Lamant L, Hieblot C, Delsol G, Touriol C.

Eur J Cancer. 2007 Mar;43(4):640-6. Epub 2007 Feb 2.


A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.

Fawal M, Armstrong F, Ollier S, Dupont H, Touriol C, Monsarrat B, Delsol G, Payrastre B, Morello D.

Blood. 2006 Oct 15;108(8):2780-8. Epub 2006 Jul 11.


ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases.

Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, Morris SW, Kennedy W, Jones SC, Sandlund JT.

Blood. 2003 Oct 1;102(7):2642-4. Epub 2003 Jun 19.


Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.

Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, Delsol G, Allouche M, Payrastre B.

Blood. 2004 Feb 15;103(4):1464-71. Epub 2003 Oct 16.


Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.

Coluccia AM, Perego S, Cleris L, Gunby RH, Passoni L, Marchesi E, Formelli F, Gambacorti-Passerini C.

Blood. 2004 Apr 1;103(7):2787-94. Epub 2003 Dec 4.


Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.

Jäger R, Hahne J, Jacob A, Egert A, Schenkel J, Wernert N, Schorle H, Wellmann A.

Anticancer Res. 2005 Sep-Oct;25(5):3191-6.


Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.

Wan W, Albom MS, Lu L, Quail MR, Becknell NC, Weinberg LR, Reddy DR, Holskin BP, Angeles TS, Underiner TL, Meyer SL, Hudkins RL, Dorsey BD, Ator MA, Ruggeri BA, Cheng M.

Blood. 2006 Feb 15;107(4):1617-23. Epub 2005 Oct 27.


Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.

Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, De Wolf-Peeters C, Wlodarska I, Morris SW.

Blood. 2000 Mar 15;95(6):2144-9.


Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma.

Li C, Takino H, Eimoto T, Ishida T, Inagaki A, Ueda R, Suzuki R, Yoshino T, Nakagawa A, Nakamura S, Inagaki H.

Mod Pathol. 2007 Jun;20(6):648-55. Epub 2007 Apr 20.


Model of inhibition of the NPM-ALK kinase activity by herbimycin A.

Turturro F, Arnold MD, Frist AY, Pulford K.

Clin Cancer Res. 2002 Jan;8(1):240-5.


Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.

Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY.

Blood. 1997 Feb 15;89(4):1394-404.


Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.

Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW, Skorski T.

Cancer Res. 2001 Sep 1;61(17):6517-23.

Supplemental Content

Support Center